Search Results for keywords:"Director's Order

The Food and Drug Administration (FDA) issued a permanent debarment order against Alec Burlakoff under the Federal Food, Drug, and Cosmetic Act. Burlakoff was convicted of a felony involving illegal activities with a drug called SUBSYS while working at Insys Therapeutics. His actions included bribing doctors to prescribe the drug, often to patients who did not have cancer. As a result, Burlakoff is banned from providing services related to drug product applications, and there are penalties for any approved drug product applications that employ him during this period.

An Executive Order issued on March 27, 2025, allows the Secretary of the Department of Veterans Affairs (VA) to suspend parts of a previous Executive Order for certain VA subdivisions. This change means employees in those subdivisions, who are represented by specific labor organizations, will now be covered by the Federal Service Labor-Management Relations Statute. The Secretary agrees with the President's view that the VA's primary function is related to national security, making it impractical to fully apply certain employment laws within the VA. The suspension is effective starting from its publication date.

The Drug Enforcement Administration (DEA) has decided to revoke Dr. Yogesh Patel's DEA registration because he is not permitted to handle controlled substances as he lacks the authority to practice medicine in Colorado. The DEA's Order to Show Cause indicated that Dr. Patel's Colorado medical license is restricted, preventing him from practicing medicine, which is a critical requirement for maintaining his DEA registration. Dr. Patel did not request a hearing or dispute these allegations, leading to the revocation of his registration and denial of any pending applications. This decision was finalized by Acting Administrator Derek Maltz and will take effect on March 17, 2025.

The executive order, identified as Executive Order 14146, partially revokes certain sections of a previous order, Executive Order 13961, which was related to federal mission resilience. Specifically, sections 1, 3, 4, 5, and 7 of Executive Order 13961 are revoked, while the remaining sections are renumbered and amended. The changes do not affect existing legal authority or create any new rights or legal claims against the United States or its entities. This order ensures implementation is in line with existing laws and available budget.

The Drug Enforcement Administration (DEA) issued an Order to Show Cause to Soroosh Armandi, D.O., proposing to revoke his DEA registration because he no longer has the authority to handle controlled substances in California. Despite being notified, Dr. Armandi did not request a hearing to contest this action. His California medical license has been revoked, making him ineligible to maintain a DEA registration. As a result, the DEA has decided to revoke his DEA Certificate of Registration and deny any pending applications for renewal or additional registrations in California.

The Drug Enforcement Administration (DEA) has decided to revoke Joely Keen's DEA registration because she is no longer authorized to handle controlled substances in Texas. Her licenses to practice as an advanced practice registered nurse (APRN) and registered nurse in Texas have been revoked, and she lacks a necessary prescriptive authority agreement with a supervising physician. Without these, she cannot legally prescribe or dispense controlled substances, resulting in the loss of her DEA registration. The order becomes effective on April 28, 2025.

The Drug Enforcement Administration (DEA) issued an order to revoke Dr. David Israel's registration to handle controlled substances after he was found to lack the authority to practice medicine in New York. This decision was based on his failure to request a hearing and allegations that he issued prescriptions outside the usual course of professional practice and for non-legitimate medical purposes. Dr. Israel also allegedly allowed another individual to use his credentials to issue prescriptions unlawfully. His registration revocation is seen as consistent with ensuring public safety and compliance with the Controlled Substances Act.

The U.S. Department of Justice and the Drug Enforcement Administration took action against Dr. David Bockoff, resulting in the revocation of his license to prescribe controlled substances. This decision came after a hearing revealed he had violated standards of care in prescribing powerful drugs without proper medical examinations or documentation. The government's investigation showed that between January 2020 and June 2022, he frequently prescribed these drugs in a manner inconsistent with both federal and California laws. Dr. Bockoff did not successfully challenge these findings or take responsibility, leading to the conclusion that his practices were dangerous to public health.

The Drug Enforcement Administration (DEA) has decided to revoke John Stanton, M.D.'s DEA registration because his medical license in Tennessee was revoked, meaning he can't legally handle controlled substances in the state. An Order to Show Cause was issued previously, suggesting the removal of his DEA Certificate of Registration, as he didn't request a hearing, leading to a default judgment. As a result, the DEA has also denied Dr. Stanton's pending applications for any new registration in Tennessee. This decision was signed by the Acting Administrator of the DEA and will take effect on May 21, 2025.

The Pecan Promotion, Research, and Information Order was established to help boost the pecan industry in the United States. It introduces a system to collect assessments from producers and importers to fund marketing campaigns and research aimed at increasing demand for pecans. The rule sets up a governing Board to oversee these activities and requires a referendum after three years to decide on the continuation of the order. While most of the industry supports this program, there are concerns about the financial burden on producers due to existing marketing orders.